Skin tests in urticaria/angioedema and flushing to Pfizer-BioNTech SARS-CoV-2 vaccine: Limits of intradermal testing

Article Allergy

EAACI statement on the diagnosis, management and prevention of severe allergic reactions to COVID-19 vaccines

Milena Sokolowska et al.

Summary: The discussion focuses on the management and prevention of vaccine allergic reactions, providing a detailed algorithm for diagnosing and treating severe allergic reactions, along with recommendations for appropriate medications and equipment. A workup for identifying potential allergenic components in vaccines is proposed, along with a suggested international collaborative approach to reduce the risk of allergic reactions to COVID-19 vaccines.

ALLERGY (2021)

Add to Collection

Editorial Material Medicine, General & Internal

Allergic Reactions Including Anaphylaxis After Receipt of the First Dose of Pfizer-BioNTech COVID-19 Vaccine

Tom Shimabukuro et al.

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2021)

Add to Collection

Letter Allergy

Excipients as Potential Agents of Anaphylaxis in Vaccines: Analyzing the Formulations of Currently Authorized COVID-19 Vaccines

M. L. Caballero et al.

JOURNAL OF INVESTIGATIONAL ALLERGOLOGY AND CLINICAL IMMUNOLOGY (2021)

Add to Collection

Article Public, Environmental & Occupational Health

Allergic Reactions Including Anaphylaxis After Receipt of the First Dose of Pfizer-BioNTech COVID-19 Vaccine - United States, December 14-23, 2020

Tom Shimabukuro

MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT (2021)

Add to Collection

Review Dermatology

Skin tests in the diagnosis of adverse drug reactions

Luca Stingeni et al.

GIORNALE ITALIANO DI DERMATOLOGIA E VENEREOLOGIA (2020)

Add to Collection

Article Allergy

Skin test concentrations for systemically administered drugs - an ENDA/EAACI Drug Allergy Interest Group position paper

K. Brockow et al.

ALLERGY (2013)

Add to Collection

Skin tests in urticaria/angioedema and flushing to Pfizer-BioNTech SARS-CoV-2 vaccine: Limits of intradermal testing

Related references

EAACI statement on the diagnosis, management and prevention of severe allergic reactions to COVID-19 vaccines

Allergic Reactions Including Anaphylaxis After Receipt of the First Dose of Pfizer-BioNTech COVID-19 Vaccine

Excipients as Potential Agents of Anaphylaxis in Vaccines: Analyzing the Formulations of Currently Authorized COVID-19 Vaccines

Allergic Reactions Including Anaphylaxis After Receipt of the First Dose of Pfizer-BioNTech COVID-19 Vaccine - United States, December 14-23, 2020

Skin tests in the diagnosis of adverse drug reactions

Skin test concentrations for systemically administered drugs - an ENDA/EAACI Drug Allergy Interest Group position paper

Export Citation

Share Paper